Protein tyrosine kinases from inhibitors to useful drugs
Leading researchers, from the Novartis group that pioneered Gleevec/Glivec (TM) and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibit...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Book |
| Language: | English |
| Published: |
Totowa, N.J.
Humana Press
2006
|
| Series: | Cancer drug discovery and development
|
| Subjects: | |
| Online Access: | Click Here to View Status and Holdings. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Add Tag Be the first to leave a comment!
Targeting protein kinases for cancer therapy